Breaking News
Start for Free 0
Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 place See list
Close

Aridis Pharmaceuticals Inc (ARDS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.010 0.000    0.00%
22/07 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.010 - 0.010
Aridis Pharma 0.010 0.000 0.00%

OTC:ARDS Financials

 
Gain a comprehensive overview of Aridis Pharma financials. Assess key figures from the balance sheet and income statement. Explore essential metrics such as total assets, total liabilities, equity, revenue, and net income to understand the company’s overall financial performance.

Aridis Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 0.417 million compared to USD 0.399 million a year ago. Net loss was USD 0.083 million compared to USD 8.24 million a year ago.For the nine months, revenue was USD 21.15 million compared to USD 1.88 million a year ago. Net income was USD 5.25 million compared to net loss of USD 23.98 million a year ago. Basic earnings per share from continuing operations was USD 0.15 compared to basic loss per share from continuing operations of USD 1.35 a year ago. Diluted earnings per share from continuing operations was USD 0.11 compared to diluted loss per share from continuing operations of USD 1.35 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

ARDS Income Statement

Gross margin TTM -
Operating margin TTM -2.93%
Net Profit margin TTM -5.11%
Return on Investment TTM 0%
 Total Revenue  Net Income
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Revenue 0.417 19.65 1.08 1.21
Gross Profit 0.242 14.98 -4.45 -5.57
Operating Income -0.869 13.67 -6.26 -7.19
Net Income -0.083 12.14 -6.82 -6.39

ARDS Balance Sheet

Quick Ratio MRQ 0.03
Current Ratio MRQ -
LT Debt to Equity MRQ 0%
Total Debt to Equity MRQ -41.01%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Assets 6.53 6.48 9.43 14.7
Total Liabilities 18.34 21.4 37.32 38.93
Total Equity -11.8 -14.91 -27.88 -24.23

ARDS Cash Flow Statement

Cash Flow/Share TTM -0.4
Revenue/Share TTM 0.5
Operating Cash Flow  -5.62%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -0.983 -4.34 -4 -8.56
Cash From Investing Activities 0 0.014 -0.049
Cash From Financing Activities 0.999 3.03 0.263 11.03
Net Change in Cash 0.016 -1.3 -3.74 2.43
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ARDS Comments

Write your thoughts about Aridis Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email